Advertisement

Topics

Sartorius Company Profile

19:25 EDT 20th March 2019 | BioPortfolio

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Around 7,000 people work for the Group, which has its own manufacturing and sales sites in around 110 countries.


News Articles [63 Associated News Articles listed on BioPortfolio]

Sartorius continues to grow by double digits

Sartorius continued on the growth track, with double-digit gains in sales revenue and earnings. “In the first nine months of 2018, Sartorius achieved excellent organic growth,” said Dr. Joachim Kr...

Sartorius Stedim Biotech und Lonza modifizieren Zusammenarbeit beim Zellkulturmedien-Geschäft

Sartorius Stedim Biotech bietet weiterhin Lonza-Zellkulturmedien und -Pufferlösungen an, aber nicht exklusiv Sartorius Stedim Biotech wird Lonzas Vorzugslieferant für Bioprozess-Equipment und Verb.....

Genedata Licenses its Bioprocess Software Platform to Sartorius Stedim Cellca

Genedata, a leading provider of advanced software solutions for biopharma R&D, today announced that Sartorius Stedim Cellca GmbH, a subsidiary of Sartorius Stedim Biotech (SSB) and a specialist for ce...

Lonza, Sartorius Modify Cell Culture Supply Pact

Sartorius will continue to offer Lonza products under a non-exclusive agreement

Abzena Selects Sartorius as U.S. Equipment Supplier

Sartorius Stedim will equip Abzena's CDMO facilities in Bristol, PA and San Diego, CA with end-to-end process solutions

Repligen Corporation; Sartorius Stedim Biotech: Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors

Development collaboration integrates Sartorius Stedim Biotech's BIOSTAT STR bioreactors and Repligen's XCell ATF cell retention control technologyCustomers to benefit from simplified, scalable solu...

Repligen Corporation; Sartorius Stedim Biotech: Sartorius Stedim Biotech und Repligen Corporation gehen Partnerschaft zur Einführung perfusionsfähiger Bioreaktoren der nächsten Generation ein

Entwicklungszusammenarbeit stattet BIOSTAT STR-Bioreaktoren von Sartorius Stedim Biotech mit der XCell ATF-Steuerungstechnologie zur Zellrückhaltung von Repligen ausKunden profitieren von vereinfac.....

Sartorius Stedim Biotech SA: Information on Document Availability

Dow Jones received a payment from EQS/DGAP to publish this press release. Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Information on Document Availability 19-Feb-2019 / 07:34 CET/CEST...

Drugs and Medications [0 Results]

None

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study

Background: Treatment options are limited for patients with hidradenitis suppurativa (HS). Apremilast, an oral phosphodiesterase 4 inhibitor, may offer an attractive therapeutic option for patients wi...

Mast cells in hidradenitis suppurativa: a clinicopathological study.

Mast cells (MC) have been observed in hidradenitis suppurativa (HS) lesions. Their potential role in the pathogenesis of HS is unknown. The aim of this study was to assess the number and distribution ...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Postoperative Management of Groin Flaps for Vascular Coverage

This is a randomized controlled trial designed to analyze the impact of bedrest duration on return to functional independence at discharge following sartorius flap for coverage of vascular...

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 week...

Femoral Nerve Block: Anatomical Insertion Point - A Prospective Randomised Double-Blind Controlled Trial

Nerve blocks are an effective way to control pain after surgery. There are two major nerves that provide sensation to the knee: the femoral nerve provides sensation to the front of the kne...

Companies [8 Associated Companies listed on BioPortfolio]

Sartorius Corporation

Sartoris ranks among the international market and technology leaders in the fields of mechatronics, biotechnology and environmental technology. Sartorius is now a group of DIN ISO 9001 certified compa...

Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess So...

Sartorius AG

The Sartorius Group is an internationally leading laboratory and process technology supplier covering the segments of biotechnology and mechatronics. In 2005, the technology group earned sales revenue...

Sartorius Electronics

Nil

Sartorius Stedim Biotech

21.1

More Information about "Sartorius" on BioPortfolio

We have published hundreds of Sartorius news stories on BioPortfolio along with dozens of Sartorius Clinical Trials and PubMed Articles about Sartorius for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sartorius Companies in our database. You can also find out about relevant Sartorius Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record